MD3 IMPACT OF MEDICARE PART D DOUGHNUT HOLE ONTHE USE OF MEDICATIONS BY THERAPEUTIC CLASSES FOR STANDARD BENEFICIARIES  by Sun, SX & Lee, KY
dent pharmacies in Texas to 24,576 dual eligible patients. Percent
gross margin was compared between Medicaid and Medicare
Part D claims as well as among several popular Prescription Drug
Plan (PDP) sponsor claims. RESULTS: The mean percent gross
margin for prescriptions dispensed before Part D (Medicaid
claims) was 26.7%. The mean percent gross margin for claims
dispensed after Part D (Medicare claims) was 17.0% (using
ingredient costs in 2006 dollars) or 20.4% (using ingredient costs
adjusted to 2005 dollars), a reduction of 36.3% and 23.6%,
respectively. Among the ﬁve PDP sponsors identiﬁed as having
the greatest number of claims in the sample, the mean percent
gross margin ranged from 12.0% to 19.8%. Regression analysis
conﬁrmed that the PDP sponsor, in addition to the proportion of
generic drugs dispensed, is a signiﬁcant predictor of a pharmacy’s
overall percent gross margin. CONCLUSION: These ﬁndings
support pharmacy assertions of lower reimbursements from
Medicare Part D payers compared with Medicaid payers. Based
on these ﬁndings, pharmacies can respond to this new environ-
ment by accepting Part D plans with higher average percent gross
margins and increasing the proportion of generic drugs dispensed
to Medicare beneﬁciaries.
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OBJECTIVE: The standard Medicare Part D beneﬁt includes a
“doughnut hole” in coverage. Standard beneﬁt beneﬁciaries who
fall into this gap are responsible for the total costs of their
prescription drugs. The objective of this study was to evaluate the
impact of doughnut hole on the use of medications by therapeu-
tic classes. METHODS: A difference-in-difference (DID) study
approach was used. De-identiﬁed data from January 1, 2006 to
December 31, 2006 were obtained from a pharmacy beneﬁt
management database. The study group included standard
beneﬁt beneﬁciaries who reached the doughnut hole in a time
period from June 1 to October 31, 2006. The control group
included beneﬁciaries enrolled in commercial prescription drug
plans without coverage gaps. Changes in prescription days per
month, out-of-pocket costs per month, and generic utilization
rates by therapeutic classes were targeted outcome measures.
RESULTS: After controlling for demographics, disease condi-
tions and secular trend of drug use, the Part D doughnut hole was
found to be associated with reductions in use of antiasthmatics
(-3.08 prescription days per month, p < 0.0001), antineoplastics
(-2.70, p < 0.0001), antipsychotics (-1.77, p = 0.0630), anti-
diabetic drugs (-1.63, p = 0.0010), anticonvulsants (-1.49,
p = 0.0042), antidepressants (-1.11, p = 0.0011), antihyperlipi-
demics (-1.09, p < 0.0001), but slight increase in use of antivirals
(0.08, p = 0.9011) and opioid analgesics (0.05, p = 0.8503). The
Part D doughnut hole was also associated with signiﬁcant
increases in the average out-of-pocket costs for all therapeutic
classes and increases in generic utilization rates for all classes
except opioid analgesics. CONCLUSION: Standard Part D ben-
eﬁciaries in the doughnut hole signiﬁcantly reduced use of medi-
cations for potentially disabling and life-threatening conditions,
but increased spending on medications for potentially less life-
threatening conditions. This raises concern for an increased risk
of adverse health events.
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OBJECTIVE: To examine the changes in Medicare Part B drug
utilization and expenditures associated with the reduction in
physician reimbursement for Part B drugs between 2003 and
2005 and availability of drug alternatives through Medicare Part
D in 2006. This study speciﬁcally focuses on Part B biologics for
rheumatoid arthritis (RA) since they faced both these changes
introduced by the Medicare Modernization Act(MMA) of 2003.
METHODS: We used the 2002 to 2006 Medicare 5% ﬁles which
contain fee-for-service claims and enrollment data for a 5%
random sample of the Medicare population. We examined ben-
eﬁciaries with an RA diagnosis (ICD-9-CM 714.xx) in each year.
Inﬂiximab, the only Part B covered RA biologic available pre-
MMA, was identiﬁed using HCPCS codes. We tracked national
trends in its prevalence of use, number of claims, and total
payments(in 2004 dollars) across 2002 to 2006. Multivariate
regressions with standard errors corrected for repeated observa-
tions were estimated. RESULTS: We identiﬁed 0.65 to 0.81
million RA patients in 2002 to 2006. The prevalence of inﬂix-
imab use increased from 4.6% to 5.8% between 2002 and 2004
and then declined to 5.0% in 2005 and 5.2% in 2006 (p < 0.05).
The number of inﬂiximab claims per user increased from 2002 to
2004 (p < 0.05); however, there was no signiﬁcant change across
2004 to 2006. As expected, the average payment per claim
reduced by 10% from 2004 to 2005. As a result, total payments
for inﬂiximab declined from $512 million in 2004 to $459
million in 2005. Total payments per user reduced from $12,443
in 2004 to $11,194 in 2005 (p < 0.05). There was no signiﬁcant
difference in any payment measure between 2005 and 2006.
Adjusted analyses conﬁrmed these ﬁndings. CONCLUSION:
Inﬂiximab use and expenditures declined modestly after the
introduction of the average sales price based reimbursement
system in 2005. No changes were observed after the introduction
of Medicare Part D in 2006.
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OBJECTIVE: To examine the real world impact of antipsychotics
onweight gain in adolescent patients (12–19 years) taking second-
generation (SGA) or ﬁrst-generation antipsychotics (FGA).
METHODS: Naïve monotherapy patients receiving FGA’s or
SGA’s between July 1999 and March 2006 were identiﬁed using
the GE Centricity electronic medical record database; patients on
clozapine or depot antipsychotics were excluded. Baseline Body
Mass Index (BMI) recorded within 90 days prior and closest to
index prescription date was compared with maximum BMI
obtained during the follow-up period (at least 90 days to end of
study period or monotherapy period). Multivariate linear and
logistic regressions were conducted to estimate the magnitude of
weight gain and odds of 5%, 10%, 15%, and 20% increase in
BMI. To account for growth, BMI was normalized by calculating
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